Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
about
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosisInteraction between Cannabinoid System and Toll-Like Receptors Controls InflammationSativex-induced neurobehavioral effects: causal or concausal? A practical advice!HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.Self-medication of achalasia with cannabis, complicated by a cannabis use disorder.Training and Practices of Cannabis Dispensary StaffSativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats.Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization.Early phytocannabinoid chemistry to endocannabinoids and beyond.Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats.Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.
P2860
Q26770823-C49E481A-81C0-4325-A7F1-611F0BB5B840Q28066215-2523E38B-6B7E-4A96-9CA3-254C10A934F4Q35532043-806F6E25-DA36-48E0-B7E6-418223C99963Q36077672-F9E8B388-BAE3-4A85-8960-8E63BE65688CQ37306421-46E30E03-2119-4843-87E5-91B7FEF9FA54Q38261541-1429E5D3-5D41-41B4-90E8-98A29A92A24BQ38520997-5453DC83-9A80-47D9-AB33-3D7BA1066B52Q38957531-B8751AE0-66BB-40A8-BFD9-3CBA236374BFQ39150365-DBAFA948-06FC-4EAD-AB37-13EA1947AE79Q40879016-39EFE8FB-62B8-40D5-B1F8-948715BD0C3DQ41152416-7D8937A1-006F-4E13-8810-18A0A587E723Q41383917-DB3D0CFE-45E6-403C-9714-151E8ADC80BEQ42293278-0307EDCB-7424-4E4A-80DE-E7D1A30E81EDQ47997179-0734C457-2622-4EDF-9B3F-A91EE98B91FFQ48062717-F0D9AD4A-E552-4B23-95CA-A67137B3BAD0Q48325031-22B8CB54-68F8-4AC3-9229-D1403286B3F4Q48554606-3CC9FEFC-8566-4C0C-B5F1-4EDDAE04C70EQ55333056-096313F1-0D9C-42E8-9E73-42D40E142A2A
P2860
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Delta-9-tetrahydrocannabinol/c ...... ity due to multiple sclerosis.
@en
type
label
Delta-9-tetrahydrocannabinol/c ...... ity due to multiple sclerosis.
@en
prefLabel
Delta-9-tetrahydrocannabinol/c ...... ity due to multiple sclerosis.
@en
P2860
P921
P1433
P1476
Delta-9-tetrahydrocannabinol/c ...... ity due to multiple sclerosis.
@en
P2093
Kate McKeage
Yahiya Y Syed
P2860
P2888
P304
P356
10.1007/S40265-014-0197-5
P577
2014-04-01T00:00:00Z
P6179
1029077904